Leukapheresis Procedures to Study HIV-Specific Immunity [HIV+ Long-Term Non-Progressor (LTNP) Study] Print E-mail
Written by webmaster   
Monday, 11 October 2010 19:57

Leukapheresis Procedures to Study HIV-Specific Immunity

[HIV+ Long-Term Non-Progressor (LTNP) Study]

Laboratory of Immunoregulation

National Institutes of Allergy & Infectious Diseases (NIAID)

National Institutes of Health (NIH)

Principal Investigator:  Stephen A. Migueles, M.D.

 

Clinical Research Coordinator
Nancy Cogliano, RN, BSN, MA
301-435-7937

800-772-5464

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Patient Educator/Recruiter

Rocco Caldararo, BA

301-402-3481

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

http://www3.niaid.nih.gov/Volunteer/HIVlongTerm/

Del.icio.us     Digg This!     Facebook     Google     Reddit     Stumble It!
 

Please Donate!

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.
 

CROI 2011

  • Wednesday 9th March 2011
    This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at www.aidsmap.com/croi2011, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
  • Thursday 3rd March 2011
    There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
  • Wednesday 2nd March 2011
    A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the

Follow Us

  • Facebook Page: zephyrfoundation.org
  • Twitter: zephyrfound
  • YouTube: zephyrfoundation

Latest News

Studies

Controllers in Study

Donation Thermometer
Donation Thermometer
Donation Thermometer
86%

Our Goal:
2000
Currently:
1725
Updated:
December 30, 2009

Current Breakdown: 505 Elite Controllers 1009 Viremic Controllers 211 Other

Zephyr Tweets

zephyrfound: UCSF Study: "limited evidence" for substantial cardio dysfunction in elite controllers, due to inflammation.... http://t.co/2JKRTIpSml

zephyrfound: Question: When the 16 controllers in the UCSF study "elected to continue" ART-therapy, did study staff inform... http://t.co/GyzL4srV2A

zephyrfound: CROI-2013: UCSF "Treat Elite" Study Smack-down: "Limited clinical application" and "concern that HIV drugs may... http://t.co/vovoBuVFqB

zephyrfound: Latest news coming from the International AIDS Conference in Washington, DC.... http://t.co/TdvtLJgt